Business Context and Reporting Period
Kodiak Sciences Inc. (KOD) is a clinical-stage biopharmaceutical company focused on developing transformative therapeutics for retinal diseases. This Form 10-Q covers the quarterly period ended September 30, 2025. The Company has no products approved for commercial sale and has not generated any product revenue to date. Its primary activities involve the research and development of its lead product candidates: tarcocimab, KSI-501, and KSI-101.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(61.5) million | $(43.9) million | $(173.2) million | $(132.1) million |
| Net Loss Per Share | $(1.16) | $(0.84) | $(3.28) | $(2.51) |
| Research & Development Expenses | $50.5 million | $31.9 million | $136.9 million | $94.3 million |
| General & Administrative Expenses | $11.9 million | $14.8 million | $40.1 million | $46.3 million |
| Cash and Cash Equivalents (Sept 30, 2025) | $72.0 million | |||
| Accumulated Deficit (Sept 30, 2025) | $(1,502.0) million | |||
| Net Cash Used in Operating Activities (YTD) | $(96.6) million | $(87.2) million |
Material Changes vs. Prior Period
- Increased R&D Spend: Research and development expenses increased by $18.6 million (58%) in Q3 2025 compared to Q3 2024. This was driven by increased costs for the ongoing DAYBREAK Phase 3 clinical trial and manufacturing activities for tarcocimab, as well as expanding clinical activities for KSI-501 and KSI-101.
- Decreased G&A Spend: General and administrative expenses decreased by $2.9 million in Q3 2025 compared to the prior year, primarily due to lower stock-based compensation and reduced net rent expense following the sublease of a corporate office building.
- Widening Net Loss: The net loss for the nine months ended September 30, 2025, increased by $41.1 million compared to the same period in 2024, reflecting the acceleration of clinical development programs.
- Cash Burn: Cash and cash equivalents decreased from $168.1 million at December 31, 2024, to $72.0 million at September 30, 2025, representing a significant drawdown in liquidity.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has stated there is substantial doubt regarding the Company's ability to continue as a going concern. The Company believes its existing cash resources may not be sufficient to meet anticipated operating and capital expenditure requirements for the 12 months following the report date. Additional financing will be required.
- Clinical Milestones:
- Tarcocimab: Topline data for the GLOW2 study (Diabetic Retinopathy) is expected in Q1 2026. Topline data for the DAYBREAK study (Wet AMD) is expected in Q3 2026. A single Biologics License Application (BLA) is planned for 2026.
- KSI-101: Topline data for the PEAK and PINNACLE Phase 3 studies (Macular Edema Secondary to Inflammation) are expected in Q4 2026 and Q1 2027, respectively.
- Key Risks:
- Capital Requirements: Failure to secure additional financing could force the Company to pause, scale back, or discontinue development programs.
- Clinical Trial Outcomes: The Company's prospects are heavily dependent on the success of tarcocimab, KSI-501, and KSI-101. Previous trials (GLEAM/GLIMMER) failed to meet primary endpoints, highlighting the risk of future trial failure.
- Manufacturing and Supply Chain: Reliance on third-party manufacturers (Lonza) and single-source suppliers for raw materials introduces supply chain risks.
- Regulatory Uncertainty: Approval processes are lengthy and unpredictable; the Company has no approved products.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for when current cash reserves ($72.0 million) will be depleted and the status of any ongoing fundraising efforts.
- Clinical Trial Enrollment: Confirm that enrollment for the pivotal GLOW2, DAYBREAK, PEAK, and PINNACLE studies remains on track and that no safety holds have been issued.
- Sublease Impact: Review the details of the sublease agreement for the Palo Alto facility to understand the net impact on rent expenses and the $1.9 million impairment charge recorded in Q1 2025.
- Manufacturing Capacity: Assess the status of the custom-built Ursus Facility and the Company's ability to scale manufacturing for commercial launch if approval is granted.
- Regulatory Strategy: Monitor FDA communications regarding the sufficiency of the planned single BLA for tarcocimab across multiple indications (Wet AMD, DR, RVO).